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Background: Pheochromocytoma and paragangliomas (PPGL) are hereditary in approximately 30% to 40% cases. With the ad-
vancement of genetic analysis techniques, including next-generation sequencing (NGS), there were attempts to classify PPGL into 
molecular clusters. With NGS being applied to clinical settings recently, we aimed to review the results of genetic analysis, including 
NGS, and investigate the association with clinical characteristics in Korean PPGL patients. 
Methods: We reviewed the medical records of PPGL patients who visited Severance hospital from 2006 to 2019. We documented 
the clinical phenotype of those who underwent targeted NGS or had known germline mutations of related genes. 
Results: Among 57 PPGL patients, we found 28 pathogenic germline mutations of susceptibility genes. Before the targeted NGS 
was implemented, only obvious syndromic feature lead to the Sanger sequencing for the specific genes. Therefore, for the exact 
prevalence, only patients after the year 2017, when targeted NGS was added, were included (n=43). The positive germline muta-
tions were found in 14 patients; thus, the incidence rate is 32.6%. Patients with germline mutations had a higher likelihood of family 
history. There were significant differences in the type of PPGLs, percentage of family history, metastasis rate, presence of other tu-
mors, and biochemical profile among three molecular clusters: pseudohypoxic tricarboxylic acid cycle-related, pseudohypoxic von 
Hippel-Lindau (VHL)/endothelial PAS domain-containing protein 1-related, and kinase-signaling group. Germline mutations were 
identified in seven PPGL-related genes (SDHB, RET, VHL, NF1, MAX, SDHA, and SDHD).
Conclusion: We report the expected prevalence of germline mutations in Korean PPGL patients. NGS is a useful and accessible tool 
for genetic analysis in patients with PPGLs, and further research on molecular classification is needed for precise management.
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INTRODUCTION
Pheochromocytoma (PCC) and paraganglioma (PGL) are tu-
mors originating from chromaffin cells in the adrenal medulla 
and extra-adrenal paraganglia of the sympathetic and parasym-
pathetic nervous chains, respectively [1]. These neuroendocrine 
tumors are collectively referred to as pheochromocytoma and 
paraganglioma (PPGL). PCCs and sympathetic PGLs can syn-
thesize and secrete catecholamines, mainly adrenaline and nor-
adrenaline, and even dopamine, as they originate from neuroen-
docrine cells derived from the embryonic neural crest, while 
parasympathetic PGLs rarely produce catecholamines [2,3]. 
PPGLs are rare tumors with a incidence of 0.95 per 100,000 
person-years in the United States. They account for 0.02% to 
0.5% of patients with hypertension [4]. Classically, PCC was 
called “10% tumor,” as this tumor had a 10% rate of malignan-
cy, bilateral occurrence, pediatric-onset, being asymptomatic, 
familial inheritance, and having an extra-adrenal location [5,6]. 
Regarding the pathogenesis, 90% of PCCs were considered 
sporadic, with only 10% being hereditary with germline muta-
tions [7]. However, this rule was disproved as techniques for 
genetic testing evolved, and the prevalence of PPGL with germ-
line mutations was reported to be approximately 30% to 40% 
[8-10]. 
A traditional familial cause of PPGL was noted in syndromes 
such as multiple endocrine neoplasia (MEN) type IIA and IIB, 
neurofibromatosis (NF) type 1, and von Hippel-Lindau (VHL) 
disease [5]. However, with the advancement of genetic analysis 
techniques, more susceptibility genes for hereditary PPGL syn-
dromes have been discovered. Mutations in subunits of the suc-
cinate dehydrogenase (SDH) complex, a mitochondrial enzyme 
for oxidative phosphorylation [11], is now a well-known cause 
of hereditary PPGL [12,13]. An astonishing feature of heredi-
tary PPGLs is the associated high degree of genetic heterogene-
ity. Some of the susceptibility or driver genes, mutations known 
to cause hereditary PPGLs [9], are involved in the hypoxic re-
sponse during cellular metabolism. Others are involved in ki-
nase signaling pathways [14]. Due to the complexity of analyz-
ing the genetics of PPGLs, there has been an attempt to ap-
proach this issue by classifying the genes into molecular clus-
ters: pseudohypoxia, Wnt signaling, and kinase signaling group 
[15].
The high prevalence of PPGLs is known to be caused by a 
certain germline mutation of susceptibility genes, making them 
the most heritable tumor in humans [9]. Therefore, genetic test-
ing is recommended in all patients regardless of family history 
[16]. Genetic testing has become more accessible with the utili-
zation of next-generation sequencing (NGS), an accurate, fast, 
and inexpensive way of genetic testing and has shifted the para-
digm of genetic research. The NGS in PPGL (NGSnPPGL) 
study group suggested that targeted NGS is the most preferred 
method for genetic testing of PPGL patients [17]. Targeted NGS 
analyzes only the genes in the panel previously reported to have 
an association with tumorigenesis of PPGLs.
Regarding the development of valuable NGS technology, 
more susceptibility genes for hereditary PPGLs are being dis-
covered, but the relative frequencies of the mutations found to 
vary between studies and geographic locations [17-19]. More-
over, since PPGL is a very rare type of tumor, large-scale stud-
ies on clinical relationships are limited. The genotype-pheno-
type relationship has not been thoroughly examined, especially 
in Korea. Regarding the clinical features of these tumors, a 
study by Kim et al. [20] on 119 patients with PCCs from 1986 
to 2009 is so far the largest in Korea; however, it only included 
PCCs and not PGLs. Further, this study lacked information on 
the genetic aspect of this issue. Another study by Kim et al. [21] 
demonstrated a correlation between germline mutations and the 
clinical characteristics of PPGLs by examining 53 patients with 
non-syndromic PPGLs. In this study, seven patients (13.2%) 
had germline mutations: rearranged during transfection (RET; 
n=2), VHL (n=1), SDHB (n=2), and SDHD (n=2). The preva-
lence rate of germline mutations is much lower than the recently 
reported prevalence worldwide. This is due the fact that the in-
formation on germline mutations in this study was limited to 
only four genes screened by direct sequencing. Other publica-
tions on this topic are limited to case reports. Since NGS has 
been applied to the clinical hospital setting only recently in Ko-
rea, there is no report examining germline mutations of suscep-
tibility genes related to PPGLs in Korea. 
We aimed to investigate the prevalence of gene mutations 
found in PPGL patients in the Korean population and to exam-
ine its associated clinical characteristics using genetic analyses, 
including targeted NGS. To this end, we reviewed the clinical 




We reviewed the medical records of 78 patients with the histo-
pathological or clinical diagnosis of PPGLs who visited Sever-
ance Hospital, Seoul, Korea between 2006 and 2019, and have 
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been managed by a single, well-experienced endocrinology 
specialist (corresponding author Y.R.). Histopathological diag-
nosis of PPGL was based on histologic confirmation by pathol-
ogists. Four patients did not undergo surgery due to having an 
unresectable mass or individual preference. However, they were 
clinically diagnosed with PCCs because of the apparent adrenal 
mass on imaging studies such as computed tomography (CT), 
positron emission tomography, or iodine-131-labeled metaiodo-
benzylguanidine scintigraphy and elevated catecholamine level 
in the plasma or urine.
Of the 78 patients, 57 were selected for inclusion in this study 
(Fig. 1). Patients who refused to undergo any form of genetic 
testing due to personal or economic reasons were excluded 
(n=18). Also, patients who underwent Sanger sequencing, but 
no mutation was found, were excluded (n=2). These exclusion 
criteria were applied since we could not evaluate the genetic 
background or rule out the possibility of patients having other 
meaningful mutations in terms of the pathogenesis of PPGLs, 
since the Sanger sequencing included only a very limited num-
ber of genes (i.e., RET, NF1, VHL). In the same context, a pa-
tient who had a silent mutation in the RET gene by Sanger se-
quencing was also excluded (n=1) because it was considered as 
having no mutation. As a result, the included patients are those 
who underwent targeted NGS in our hospital (n=41), and those 
who had germline mutations found either by Sanger sequencing 
in our hospital (n=11) or in other hospitals (n=5). 
The medical records of the 57 patients were thoroughly re-
viewed. Information, including age, age of onset, sex, family 
history, location of the tumor, tumor size, metastasis, recurrence, 
presence of other tumors, discovery route, symptoms and signs, 
histologic examination results, and biochemical profile, were 
extracted. When a patient had at least one family member with 
PPGL or second-degree relatives with a syndrome related to 
PPGL, the patient was considered to have a family history. The 
tumor size was represented by its largest diameter measured 
histologically or on images if histological findings were not 
PPGL patients who visited Severance Hospital between 2006 and 2019, managed by a single endocrinologist (n=78)
Exclusion criteria
· Subjects who did not undergo any form of genetic analysis due to refusal (n=18)
· Subjects who underwent Sanger sequencing, but no mutation was found (n=2)
· Subjects with silent mutation of RET gene found by Sanger sequencing (n=1)
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Fig. 1. Study flow chart. PPGL, pheochromocytoma and paraganglioma; RET, rearranged during transformation; NGS, next-generation se-
quencing; VOUS, variant of unknown significance; TCA, tricarboxylic acid; VHL, von Hippel-Lindau; EPAS1, endothelial PAS domain-
containing protein 1.
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present. Only cases with distant metastasis counted as malignant 
PPGL, conservatively with high specificity but relatively low 
sensitivity [22]. It is known that distant metastasis is the only 
reliable factor that can distinguish malignant PPGL among other 
clinical, biochemical, or histological features [23,24]. The time 
at which malignancy was detected was also recorded. Recur-
rence was defined as the reappearance of PPGL, i.e., presence 
of a newly discovered mass on imaging studies with elevation 
in catecholamines levels after the complete removal of the tu-
mor by surgical resection [25,26]. Recurrence included both lo-
cal and distant recurrence. The tumor discovery route was clas-
sified as an incidental finding on CT or ultrasonography regard-
less of the presence of symptoms and suspected tumors based 
on the presenting symptoms known to correlate with PPGL 
when the patient visited the hospital. An incidental finding of a 
mass in the adrenal gland is called adrenal incidentaloma, and 
additional workup was done for further evaluation and proper 
diagnosis of the mass. Uncommon discovery routes included 
the detection of gene mutations before PCC was detected in a 
family study. For biochemical profile, plasma or 24-hour urine 
epinephrine, metanephrine, norepinephrine, normetaepinephrine, 
dopamine, and urinary vanillylmandelic acid levels were mea-
sured. PPGL was considered functional if the catecholamine lev-
els were elevated beyond the normal upper limit, adrenergic 
when epinephrine/metanephrine level was predominantly elevat-
ed; noradrenergic when norepinephrine/normetanephrine level 
was predominantly elevated; and adrenergic/noradrenergic when 
both epinephrine/metanephrine and norepinephrine/normeta-
nephrine levels were elevated. When all catecholamine levels 
were normal, the tumor was classified as silent [27]. 
The research protocol was approved by the Institutional Re-
view Board of Severance Hospital, South Korea (IRB No. 4-2019-
4088). Informed consent was waived by the board.
Genetic analyses
Targeted NGS was strongly recommended to all patients who 
were diagnosed with PPGLs as a routine test since January 2017. 
Before targeted NGS was implemented in our hospital (pre-NGS 
period), Sanger sequencing was conducted selectively in patients 
who demonstrated features of familial PPGLs, such as MEN2, 
NF1, and VHL disease. Even after adopting targeted NGS (post-
NGS period), Sanger sequencing was the diagnosis of choice for 
patients who had syndromic features that strongly implied specific 
gene mutations and family members of patients with germline 
mutations.
We conducted targeted NGS in 41 patients with PPGLs from 
March 2017 to October 2019. We used our hospital’s novel NGS 
panel to detect gene mutations of 400 genes for hereditary endo-
crine disorders (Supplemental Table S1). There were 19 PPGL-
related genes in the panel (alpha thalassemia mental retardation 
syndrome X-linked [ATRX], BRAF, Egl-9 family hypoxia-in-
ducible factor 1 [EGLN1], endothelial PAS domain-containing 
protein 1 [EPAS1], fibroblast growth factor receptor 1 [FGFR1], 
fumarate hydratase [FH], Harvey rat sarcoma viral oncogene 
homolog [HRAS], kinesin family member 1B [KIF1B], Myc-as-
sociated protein X [MAX], NF1, RET, SDH A/AF2/B/C/D 
[SDHA/SDHAF2/SDHB/SDHC/SDHD], transmembrane pro-
tein 127 [TMEM127], tumor protein 53 [TP53], and VHL) [17]. 
Our hospital’s targeted NGS followed the 2017 American Col-
lege of Medical Genetics and Genomics (ACMG) guidelines [28]. 
Of the five categories in ACMG guidelines, our hospital only 
reported three categories: pathogenic, likely pathogenic, and 
variant of unknown significance (VOUS). 
When a pathogenic or likely pathogenic mutation was found 
by targeted NGS or germline mutation of PPGL-related suscep-
tibility gene was detected by Sanger sequencing, a patient was 
considered to have mutation of known pathogenicity. If a patient 
had a mutation of known pathogenicity, the genetic analysis re-
sult counted as positive, which indicates PPGL with a germline 
mutation of a susceptibility gene. If a patient had VOUS muta-
tions only, the genetic analysis result was considered negative. 
Meanwhile, some patients had VOUS mutations of genes that 
are known to be related to the pathogenesis of PPGL. Although 
physician assumed that these VOUS of PPGL-related genes 
might have clinical significance, they were not considered posi-
tive as the pathogenicity of mutations has not been proven yet 
due to insufficient data. 
For patients with germline mutations of PPGL-related genes, 
information on mutated genes and specific loci were collected. 
Mutated genes were classified into molecular clusters as previ-
ously described: pseudohypoxia, Wnt signaling, and kinase sig-
naling group [15]. 
Family study
Family members of genetically confirmed patients were recom-
mended to undergo genetic analysis. Fourteen individuals, who 
were family members of nine PPGL patients with germline mu-
tations, underwent Sanger sequencing for the same mutation as 
detected in the respective family member with PPGL.
Statistical analysis
Clinical characteristics were presented as mean±standard devi-
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ation for parametric continuous variables, as median (interquar-
tile range) for nonparametric continuous variables, and as 
counts (percentage) for categorical variables. For continuous 
variables, the Shapiro-Wilk test was used to test for normality. 
Clinical characteristics were compared according to the genetic 
analysis results and molecular clusters of patients of all periods. 
For parametric continuous variables, comparisons were made 
using a t test between two groups and one-way analysis of vari-
ance (ANOVA) between three groups. Comparisons were con-
ducted using the Kruskal-Wallis test for nonparametric continu-
ous variables and chi-square test for categorical variables. A 
two-sided P<0.05 was considered to be statistically significant. 
All statistical analyses were performed using Stata version 14.2 
(Stata Corp., College Station, TX, USA).
RESULTS
Patient characteristics
Of the 78 patients with PPGLs, 61 patients (78.2%) were diag-
nosed with PCC, and the other 17 patients (21.8%) were diag-
nosed with PGL. After excluding patients, we extensively re-
viewed medical records of 57 patients (73.1%) who underwent 
targeted NGS or were found to have germline mutations of a 
susceptibility gene by direct sequencing. The descriptive clini-
cal characteristics of these patients are presented in Table 1. The 
mean age of onset was 42.8±14.8 years, and 31 patients 
(54.4%) were females. Forty patients (70.2%) were diagnosed 
with PCC, and the other 17 (29.8%) were diagnosed with PGL. 
The location of PCC was either the right (40.0%), left 
(40.0%), or bilateral (20.0%) adrenal glands. While three PGLs 
(17.7%) were parasympathetic as they were located in the head 
and neck region, including the mediastinum, 14 PGLs (82.4%) 
were sympathetic, located in thoracoabdominopelvic regions, 
including retroperitoneum, pancreas, para-aortic space, and 
bladder [29]. All of parasympathetic PGLs were biochemically 
silent. The median tumor size was 3.7 cm. The metastasis and 
recurrence rates were 26.3% and 19.3% for PPGL, respectively. 
Among 15 patients with metastasis, seven cases were synchro-
nous, whereas eight cases were metachronous. The site of dis-
tant metastasis included bone (n=5), lymph nodes (n=5), liver 
(n=3), and lungs (n=3). Eighteen patients (31.6%) had previ-
ously diagnosed tumors in other organs: medullary thyroid car-
cinoma (MTC, n=8), papillary thyroid carcinoma (n=3), renal 
cell carcinoma (n=3), and hemangioblastoma (n=3) among 
others. Forty-three patients presented with symptoms related to 
PPGLs, including hypertension (n=26), palpitation (n=17), 
headache (n=8), weight loss (n=6), abdominal pain (n=5), diz-
ziness (n=4), and sweating (n=3). PPGL was detected inciden-
tally by CT or ultrasonography in 21 patients (41.2%), whereas 
28 patients (54.9%) had symptoms of PPGL at the first visit. In 
two patients (3.9%), gene mutations were first detected during a 
family study, and the following workup revealed the presence 
of PCCs. Functional tumors accounted for 70.2% of the cases, 
with the noradrenergic type being the most common (52.6%). 
Germline mutations in PPGL patients 
Fourteen patients received Sanger sequencing in pre-NGS peri-
od, while the other 43 patients underwent genetic testing by ei-
ther direct sequencing (n=2) or targeted NGS (n=41) in post-
NGS period. 
Among patients of all periods, 28 patients had positive genet-
ic analysis results, as they were found with germline mutations 
of PPGL-related genes with pathogenicity, detected either by 
targeted NGS (n=2 for pathogenic, n=10 for likely pathogenic) 
or Sanger sequencing (n=16). The other 29 patients were re-
garded to have negative genetic analysis results. Among those 
with negative results, seven patients had VOUS mutations of 
susceptibility genes, while 22 patients had only VOUS muta-
tions of genes unrelated to PPGL. 
Meanwhile, to obtain a more accurate prevalence of germline 
mutations among PPGL patients, we took into consideration 
only the patients who received gene analyses during post-NGS 
period. Since 2017, the year at which targeted NGS was recom-
mended to all patients, a total of 43 PPGL patients underwent 
genetic testing (n=41 for targeted NGS, n=2 for Sanger se-
quencing). Among those 43 patients, 14 patients had positive 
results, so the proportion of germline mutations is estimated to 
be 32.6% (14 out of 43). 
Comparison of clinical characteristics, including age, age of 
onset, sex, family history, location of the tumor, tumor size, me-
tastasis, time of metastasis discovery, recurrence, presence of 
other tumors, discovery route, and biochemical profile, between 
positive and negative genetic analysis results is presented in Ta-
ble 1. PPGL patients with germline mutations were more likely 
to have a family history (P=0.001). Although not statistically 
significant, patients with germline mutations tended to have a 
lower age of onset and prevalence of bilateral PCCs and a high-
er rate of metastasis and recurrence.
Among 28 patients with positive results, 19 different germline 
mutations from seven susceptibility genes were discovered. The 
most frequently mutated genes were SDHB (n=9), followed by 
RET (n=8), VHL (n=6), NF1 (n=2), MAX (n=1), SDHA (n=1), 
Hereditary Pheochromocytoma and Paraganglioma
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and SDHD (n=1) (Fig. 2). Sixteen patients had classical famil-
ial syndromes. Of these, eight had MEN2, six had VHL syn-
drome, and two had NF type 1. Meanwhile, seven VOUS muta-
tions were found in four types of genes related to PPGL; SDHB 
(n=2), EPAS2 (n=2), KIF1B (n=1), SDHC (n=1), and TMEM127 
(n=1) (Supplemental Table S2). 
Table 1. Clinical Characteristics of Patients with PPGL According to the Genetic Analysis Result
Characteristic Total (n=57)
Genetic analysis result






Age, yrb 48.5±13.7 46.2±15.0 48.1±15.7 48.5±13.7 50.8±12.2 0.211
Age of onset, yrb 42.8±14.8 39.5±15.9 42.2±18.2 42.8±14.8 46.0±13.1 0.096
Female sex 31 (54.4) 16 (57.1) 7 (50.0) 9 (64.3) 15 (51.7) 0.681
Family history 9 (15.8) 9 (32.1) 2 (14.3) 7 (50.0) 0 0.001
Type of PPGL
PCC 40 (70.2) 20 (71.4) 7 (50.0) 13 (92.9) 20 (71.4) 0.839
PGL 17 (29.8) 8 (28.6) 7 (50.0) 1 (7.1) 8 (28.6)
Location
PCC (n=40)
Unilateral adrenal gland 32 (80.0) 14 (70.0) 4 (57.1) 10 (76.9) 18 (90.0) 0.114
Right adrenal gland 16 (40.0) 8 (40.0) 2 (28.6) 6 (46.2) 8 (40.0)
Left adrenal gland 16 (40.0) 6 (30.0) 2 (28.6) 4 (30.8) 10 (50.0)
Bilateral adrenal glands 8 (20.0) 6 (30.0) 3 (42.9) 3 (23.1) 2 (10.0)
PGL (n=17)
Head and neck 3 (17.7) 1 (12.5) 1 (14.3) 0 2 (22.2) 0.600
Othersc 14 (82.4) 7 (87.5) 6 (85.7) 1 (100.0) 7 (77.8)
Tumor size, cm (n=48)d 3.7 (2.7–4.8) 3.5 (2.0–4.6) 3.1 (2.0–4.4) 4.1 (3.2–4.7) 3.8 (3.2–5.0) 0.261
Metastasis 15 (26.3) 10 (35.7) 6 (42.9) 4 (28.6) 5 (17.2) 0.113
Synchronous 7 (12.3) 4 (14.3) 3 (21.4) 3 (21.4) 3 (10.3) 0.464
Metachronous 8 (14.0) 6 (21.4) 3 (21.4) 1 (7.2) 2 (6.9)
Recurrence 11 (19.3) 7 (25.0) 4 (28.6) 3 (21.4) 4 (13.8) 0.284
Presence of other tumors 18 (31.6) 12 (42.9) 3 (21.4) 9 (64.3) 6 (20.1) 0.072
Discovery route (n=51)
Incidental 21 (41.2) 11 (45.8) 4 (33.3) 7 (58.3) 11 (37.0) 0.224
Symptomatic 28 (54.9) 11 (45.8) 7 (58.3) 4 (33.3) 17 (63.0)
Gene mutation 2 (3.9) 2 (8.3) 1 (8.3) 1 (8.3) 0
Biochemical profile
Adrenergic/Noradrenergic 9 (15.8) 4 (14.3) 1 (7.1) 3 (21.4) 5 (17.2) 0.732
Adrenergic 1 (1.8) 1 (3.6) 0 1 (7.1) 0
Noradrenergic 30 (52.6) 14 (50.0) 9 (64.3) 5 (35.7) 16 (55.2)
Silent 17 (29.8) 9 (32.1) 4 (28.6) 5 (35.7) 8 (27.6)
Values are expressed as mean±standard deviation, number (%), or median (interquartile range).     
PPGL, pheochromocytoma and paraganglioma; NGS, next-generation sequencing; PCC, pheochromocytoma; PGL, paraganglioma.  
aP value for the correlation between positive group and negative group; bP value was calculated by t test, as they were parametric variables (Shapiro-Wilk 
test P=0.680 for age; P=0.574 for age of onset); cOthers include retroperitoneum, pancreas, para-aortic space, and bladder; dP value was calculated by 
the Mann-Whitney U test, as it was a nonparametric variable (Shapiro-Wilk test P<0.001).
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Seventeen out of the 28 positive mutations (60.7%) were mis-
sense mutations (Fig. 3). Eight mutations (28.6%) were frame-
shift mutations, and one mutation (3.6%) was a nonsense muta-
tion. 
Mutated genes with pathogenicity were classified into three 
molecular clusters: pseudohypoxic tricarboxylic acid (TCA) cy-
cle-related group including SDHB, SDHA, and SDHD (n=11); 
pseudohypoxic VHL/EPAS1-related group including VHL (n=6); 
and a kinase-signaling group including RET, NF1, and MAX 
(n=11). Clinical characteristics were compared between the mo-
lecular clusters (Table 2). The diagnosis of PCC or PGL signifi-
cantly differed between the clusters (P=0.003). While the TCA 
cycle-related group patients were comparable in terms of the 
type of PPGL (PCC 36.4% vs. PGL 63.6%), the kinase signal-
ing group consisted of PCCs only (PCC 100.0% vs. PGL 0.0%). 
Patients in the kinase signaling group were more likely to have 
a family history (63.6%), followed by those in the pseudohy-
poxic VHL/EPAS1-related group (33.3%), while the pseudohy-
poxic TCA-cycle related group had no family history (P=  
0.006). Metastasis rate was the highest in the pseudohypoxic 
TCA cycle-related group (63.6%), followed by the pseudohy-
poxic VHL/EPAS1-related group (50.0%), and the kinase sig-
naling group had no patient with distant metastasis (P=0.006). 
The kinase signaling group had the highest percentage of pa-
tients who had other tumors (72.7%), followed by the pseudo-
hypoxic VHL/EPAS1-related (50.0%) and pseudohypoxic TCA 
cycle-related (9.1%) groups (P=0.010). A significant difference 
in biochemical profile between the molecular clusters was de-
tected (P=0.036). Notably, functional PPGLs in the pseudohy-
poxic group were all noradrenergic type. Although there was no 
statistically significant difference, all the pseudohypoxic TCA 
cycle-related group cases had unilateral PCC. Head and neck 
PGL was detected in only the pseudohypoxic TCA cycle-related 
group. 
Detailed clinical and genetic characteristics, including the spe-
cific mutation loci, of patients with positive genetic analyses re-
sults are presented in Table 3. Information on patients with VOUS 
of PPGL-related genes can be found at Supplemental Table S2. 
While most of the genes have already been reported in previous 
studies, four novel mutations were discovered in the present 
study: EPAS1 c.1250G>A (p.Gly417Glu), NF1 c.6215delA 
(p.His2072LeufsTer10), NF1 c.6777del (p.Gly2260fs), and 
SDHC exon 2-6 duplication. 
Family study
Fourteen family members of nine patients underwent Sanger se-
quencing for family study. Eight of these family members 
(57.1%) had the same germline mutation as that of the patient: 
SDHB (n=4), RET (n=3), and NF1 (n=1). Those with germline 
mutations underwent screening workup, including history tak-
ing, physical examination, measurement of plasma or urine cat-
echolamine levels, and imaging such as CT for the detection of 
PPGLs. For genes known to cause syndromic diseases, further 
evaluation was performed, i.e., thyroid sonography for patients 
with RET mutation considering the possibility of MTC. As a re-
sult, two persons were newly diagnosed with PCCs. Both daugh-
ters of a patient with PCC and MEN2A (Case no. 17) had the 
same RET gene mutation. While one only had C-cell hyperpla-
sia, another (Case no. 13) was diagnosed with PCC, MTC, and 
Fig. 2. The frequency of germline mutations in susceptibility genes 
related to pheochromocytomas and paragangliomas detected in our 
study. SDH, succinate dehydrogenase; RET, rearranged during 
transformation; VHL, von Hippel-Lindau; NF1, neurofibromato-





















SDHB RET VHL NF1 MAX SDHA SDHD
Fig. 3. Overview of mutation distribution in pheochromocytoma 
and paraganglioma patients of this study. 
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MEN2A. Similarly, the daughter (Case no. 18) of a patient with 
PCC and MEN2A (Case no. 20) was found to have RET gene 
mutation and was diagnosed with PCC, MTC, and MEN2A. 
The daughter of another patient with PCC and NF1 (Case no. 
12) was also diagnosed with NF1 due to the same mutation in 
the NF1 gene; although she did not have PPGL, typical clinical 
features of neurofibromatosis, café-au-lait spots, and neurofi-
broma were noted. Four family members who had SDHB muta-
Table 2. Clinical Characteristics of Patients with PPGL According to the Molecular Clusters    
Characteristic







Age, yra 47.6±16.7 45.7±11.9 45.0±15.9 0.920
Age of onset, yra 43.2±18.7 35.8±15.3 37.8±13.8 0.616
Female sex 5 (45.5) 4 (66.7) 7 (63.6) 0.599
Type of PPGL
PCC 4 (36.4) 5 (83.3) 11 (100.0) 0.003
PGL 7 (63.6) 1 (16.7) 0
Family history 0 2 (33.3) 7 (63.6) 0.006
Location
PCC (n=20)
Unilateral adrenal gland 4 (100.0) 3 (60.0) 7 (63.6) 0.339
Right adrenal gland 2 (50.0) 1 (20.0) 5 (45.5)
Left adrenal gland 2 (50.0) 2 (40.0) 2 (18.2)
Bilateral adrenal glands 0 2 (40.0) 4 (36.4)
PGL (n=8)
Head and neck 1 (14.3) 0 0 0.686
Othersb 6 (85.7) 2 (100.0) 0
Tumor size, cm (n=23)c 4.1 (3.1–4.7) 3.5 (2.0–4.2) 3.4 (2.0–4.7) 0.688
Metastasis 7 (63.6) 3 (50.0) 0 0.006
Synchronous 2 (18.2) 2 (66.7) 0 0.260
Metachronous 5 (45.5) 1 (33.3) 0
Recurrence 4 (36.4) 2 (33.3) 1 (9.1) 0.292
Presence of other tumors 1 (9.1) 3 (50.0) 8 (72.7) 0.010
Discovery route (n=24)
Incidental 2 (25.0) 5 (83.3) 4 (40.0) 0.086
Symptomatic 6 (75.0) 1 (16.7) 4 (40.0)
Gene mutation 0 0 2 (20.0)
Biochemical profile
Adrenergic/Noradrenergic 0 0 4 (36.4) 0.036
Adrenergic 0 0 1 (9.1)
Noradrenergic 9 (81.8) 3 (50.0) 2 (18.2)
Silent 2 (18.2) 3 (50.0) 4 (36.4)
Values are expressed as mean±standard deviation, number (%), or median (interquartile range).    
PPGL, pheochromocytoma and paraganglioma; TCA, tricarboxylic acid; VHL, von Hippel-Lindau; EPAS1, endothelial PAS domain-containing protein 
1; PCC, pheochromocytoma; PGL, paraganglioma.    
aP valuewas calculated by one-way analysis of variance, as they were parametric variables (Shapiro-Wilk test P=0.699 for age; P=0.461 for age of on-
set); bOthers include retroperitoneum, pancreas, para-aortic space, and bladder; cP value was calculated by the Kruskal-Wallis test, as it was a nonpara-
metric variable (Shapiro-Wilk test P<0.001).
Choi H, et al.
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26.3% because our center is a tertiary referral hospital. Frequent 
sites of metastases were the bone, lymph nodes, liver, and lung, 
which were concordant with a previous study [33]. It is known 
that the risk of metastasis is higher in extra-adrenal location, 
with a higher level of plasma methoxytyramine (metabolites of 
dopamine), and in SDHB mutations [34-36]. Our study only 
showed a significant difference in metastatic rate depending on 
SDHB mutations. Among 15 patients with metastatic PPGL, six 
patients had SDHB mutations, three patients had VHL muta-
tions, one patient had SDHA mutation, and the other five pa-
tients were sporadic. 
A previous systematic review had shown that the incidence of 
recurrence, including local and systemic recurrence, and ap-
pearance of new tumors, is 0.95 per 100 person-years, which is 
4.7% of occurrence in 5 years [22]. One-fifth of the patients 
were found to have the recurrent disease in this study, similar to 
the previous report [20]. However, some studies have reported 
that the presence of syndromic disease, larger tumor size, and 
PGL relative to PCC being related to an increased risk of recur-
rence [22]; our study found no association between them. Ow-
ing to varying results between studies and the absence of precise 
features that predict recurrence, all patients should undergo fol-
low-up, including clinical history-taking, imaging, and bio-
chemical evaluation.
With the development of imaging techniques, the rate of inci-
dental diagnosis of PCC dramatically increased to nearly 30% 
[37]. In Korea, this rate was even higher, with 36.1% reported 
in a previous study [20]. CT was the frequently used diagnostic 
tool because the cost is lower than that in other countries due to 
the National Health Insurance System. In our study, PPGLs 
were discovered incidentally in 41.2% of the cases, showing 
that the rate of incidental diagnosis is steadily increasing. This 
phenomenon could be attributed to the growing accessibility of 
imaging procedures, including abdominal CT and sonography. 
Meanwhile, in 54.9% of the cases, the tumor was discovered 
because of the symptoms and signs. Similar to that in a previous 
study, hypertension was the most common clinical sign, where-
as palpitation and headache were the most common symptoms 
[7]. About half had either paroxysmal or sustained hypertension, 
and three-fourth of the patients had symptoms and signs associ-
ated with PPGLs. Among functional PPGLs, the noradrenergic 
type was the most common. There was no significant difference 
in the biochemical profile between PPGLs with and without 
germline mutations. 
To our knowledge, the current result on the frequency of 
germline mutations in Korean PPGL patients, 32.6%, is rela-
tions currently showed no phenotype, as no evidence of PPGL 
was found after thorough screening workup, including bio-
chemical and radiological tests, and they did not have any symp-
toms and signs. This is probably due to the low penetrance of the 
SDHB gene [30] and the possibility of delayed manifestation. 
DISCUSSION
Of the 78 Korean patients with PPGLs, we exclusively evaluat-
ed 57 patients and examined the clinical and genetic features of 
the disease. Among those 57 patients who underwent either tar-
geted NGS or Sanger sequencing, 28 patients were found to 
have pathogenic germline mutations of PPGL-related genes. 
Considering the fact that targeted NGS was implemented re-
cently as a routine modality, prevalence rate of germline muta-
tion is 32.6% (14 out of 43). There was a higher likelihood of 
family history of PPGL in patients with germline mutations than 
those with no mutations. There were significant differences in 
the type of PPGL, percentage of family history, metastasis rate, 
the presence of other tumors, and biochemical profile between 
three molecular clusters. Nineteen different germline mutations 
from seven genes (SDHB, RET, VHL, NF1, MAX, SDHA, and 
SDHD) were found, most of which were missense mutations. 
Seven patients had VOUS mutations of PPGL-related genes 
(SDHB, EPAS1, KIF1B, and SDHC). EPAS1, KIF1B, MAX, 
SDHA, SDHC, and TMEM127 mutations were the first to be re-
ported among Korean patients with PPGL.
In this study, 70.2% of patients were diagnosed with PCCs, 
while 29.8% were diagnosed with PGLs, which was in line with 
the previously reported percentage of PCC (69% to 89%) 
[18,22,31]. The mean age of onset in this study was 42.8 years, 
and 54.4% of the patients were women. This information is con-
cordant with that reported in a previous study (the peak age of 
onset, 40 to 50 years). Furthermore, PPGLs were reported to 
have an approximately equal distribution among men and wom-
en [31]. Family history was found only in nine patients (15.5%), 
all of whom were found with germline mutations. However, 
most of the patients with germline mutations did not have fami-
ly histories. A previous study also found that a high incidence of 
PCCs positive for mutations occurred without a family history 
[32]. They suggested a potential explanation for this phenome-
non: a high rate of spontaneous mutations, low penetrance of 
the gene mutations, or maternal imprinting. 
Malignant PPGL, defined as the presence of distant metasta-
sis, is reported to have a prevalence of approximately 10% [16, 
22,24]. However, in our data, the metastatic rate was as high as 
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tively higher than the previously reported prevalence in Korean 
so far (13.2%). However, this is concordant with the worldwide 
prevalence of germline mutations in PPGL known to be around 
30% to 40% [8-10]. Similar to previous studies, SDHB mutation 
was the most common [17,38]. VOUS mutations were excluded 
from significant germline mutations due to lack of data to sup-
port their pathogenicity. Indeed, VOUS mutations found in our 
study were from SDHB, EPAS1, SDHC, and TMEM127 genes, 
and except for SDHB, other genes are known to be extremely 
rare in frequencies [17,38]. Nevertheless, as VOUS indicates 
“missing pathogenicity,” the possibility of reclassification to 
other ACMG classes exists with the additional accumulation of 
clinical data [39].
We also investigated the clinical characteristics based on the 
molecular clusters. Genes were classified into three molecular 
clusters, pseudohypoxic TCA cycle-related (known to be 10% 
to 15% of PPGLs), pseudohypoxic VHL/EPAS1-related (15% to 
20%), and the kinase signaling (50% to 60%) group. In our 
study, there were significant differences in the type of PPGLs, 
percentage of family history, metastasis rate, the presence of 
other tumors, and biochemical profile. While PPGLs related to 
the TCA cycle can occur in any location, PPGLs related to VHL/
EPAS1 are not likely to be located on the head and neck areas. 
Kinase signaling-related PPGLs are most likely to be PCCs 
with an uncommon incidence of parasympathetic PGLs, and 
sympathetic PGLs are not likely to be present [15]. These find-
ings are concordant with our data that the pseudohypoxic TCA 
cycle-related group included all of PCCs, sympathetic and para-
sympathetic PGLs, but the pseudohypoxic VHL/EPAS1-related 
group only included PCCs and parasympathetic PGLs. Most of 
the patients in the kinase signaling group had PCCs except one 
with parasympathetic PGL. Our result showed that the kinase 
signaling group had 50% of family history but none in the pseu-
dohypoxic TCA cycle-related group. The discrepancies between 
the groups must be attributed to the rate of spontaneous muta-
tion and penetrance. A previous review stated that the risk of 
metastasis is highest in the pseudohypoxic TCA cycle-related 
group and lowest in the kinase signaling group, and the result 
was largely the same in our data. Pseudohypoxic TCA cycle-re-
lated PPGLs are reported to have the lowest paraganglia cell 
differentiation with a decreased expression of catecholamine-
synthesizing enzymes leading to depressed catecholamine lev-
els. Pseudohypoxic VHL/EPAS1-related PPGLs have an inter-
mediate level of catecholamine production, and kinase-signal-
ing PPGLs, being the most differentiated, are likely to be most 
functional [15]. Our study results are in line with those of a pre-
vious study, which reported that pseudohypoxic PPGLs are 
purely noradrenergic and never adrenergic because they always 
lack phenylethanolamine N-methyltransferase, an enzyme that 
catalyzes the synthesis of epinephrine from norepinephrine [15]. 
There are several limitations to this study. First, our study 
population has a small sample size in a single center, so our re-
sults might have restricted value in terms of generalization. 
However, considering the rare prevalence of PPGL, an analysis 
of 57 patients of clinical and genetic characteristics in Korea is 
noteworthy. Second, this study has a potential for biases. We in-
cluded PPGL patients managed by a single endocrinologist. Al-
though vast majority of PPGL patients in our hospital were 
treated by this physician, few patients might have been missed 
by being registered to other endocrinologists or endocrine sur-
geons. Also, we excluded two patients with no mutations and 
one patient with silent mutation analyzed by only Sanger se-
quencing but included 17 patients in whom germline mutations 
were found. This exclusion was inevitable due to the character-
istic of Sanger sequencing, by which we can only seek for mu-
tation at a gene of interest, but this could have created selection 
bias. To minimize the bias, the frequency of germline mutation 
was calculated among the patients who underwent genetic anal-
yses after the targeted NGS technique was adopted as a routine 
test. Consecutive use of targeted NGS by recommending it rou-
tinely to all the PPGL patients will be necessary for future stud-
ies. Difficult interpretation of VOUS resulted from targeted 
NGS was one of the greatest problems in our study. We ap-
proached this issue in rather conservative manner, as we consid-
ered VOUS as negative. This might have led to underestimation 
of the frequency as we acknowledge the possibility that some 
VOUS mutations might be reclassified to pathogenic or likely 
pathogenic over time with additional reports of data. Mean-
while, patients who had no mutations of susceptibility genes by 
targeted NGS cannot be considered as patients with absolutely 
negative results, as we only analyzed the known susceptibility 
genes of PPGLs. For those patients with negative results with 
NGS, we might recommend whole-genome sequencing [17]. 
Whole-exome sequencing of these patients might uncover new 
susceptibility genes that are still unknown, but the validation of 
the causative relationship between the mutation and the PPGL 
will be a difficult process. Moreover, epigenetic changes were 
not taken into consideration in this study. Previous studies have 
shown that epigenetic gene silencing of tumor suppressor genes 
due to promotor methylation is present and considered patho-
genic in some patients with PPGLs [40,41]. This finding sug-
gests that the percentage of PPGL patients with genetic back-
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870 www.e-enm.org Copyright © 2020 Korean Endocrine Society
ground might be higher than the value presented.
In conclusion, our data present the frequency of germline mu-
tations in Korean patients with PPGL. The expected prevalence 
of germline mutations of susceptibility genes in PPGL patients 
is estimated to be approximately 32.6%. With the utilization of 
NGS, genetic testing has become more accessible, simultane-
ously providing us with abundant information. Further research 
into the molecular characterization of PPGL can lead us to pur-
sue and take a step toward the concept of precision medicine.
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